Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S
Μορφή:	Conference item
Έκδοση:	American Thoracic Society 2018

Παρόμοια τεκμήρια

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2019)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
ανά: Gunsoy, N, κ.ά.
Έκδοση: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
ανά: Steven W. Yancey, κ.ά.
Έκδοση: (2019-09-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Howell, I, κ.ά.
Έκδοση: (2024)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
ανά: Ortega, H, κ.ά.
Έκδοση: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
ανά: Bel, E, κ.ά.
Έκδοση: (2014)

Mepolizumab in refractory eosinophilic asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (2010)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
ανά: Imran Howell, κ.ά.
Έκδοση: (2024-07-01)

Mepolizumab for eosinophilic COPD
ανά: Sciurba, F, κ.ά.
Έκδοση: (2018)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
ανά: Price, D, κ.ά.
Έκδοση: (2019)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
ανά: Yancey, S, κ.ά.
Έκδοση: (2016)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
ανά: Jiang-Hua Li, κ.ά.
Έκδοση: (2021-08-01)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
ανά: David B. Price, κ.ά.
Έκδοση: (2019-08-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
ανά: Pavord, I
Έκδοση: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
ανά: Ortega, H, κ.ά.
Έκδοση: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
ανά: Haldar, P, κ.ά.
Έκδοση: (2009)

Biomarkers for severe eosinophilic asthma.
ανά: Yancey, S, κ.ά.
Έκδοση: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
ανά: Moran, AM, κ.ά.
Έκδοση: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
ανά: Ian D. Pavord, κ.ά.
Έκδοση: (2022-05-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
ανά: Arian Ghassemian, κ.ά.
Έκδοση: (2021-01-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
ανά: Pavord, I, κ.ά.
Έκδοση: (2017)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
ανά: Jie Gao, κ.ά.
Έκδοση: (2018-05-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
ανά: Terufumi Shimoda, κ.ά.
Έκδοση: (2017-07-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
ανά: Connolly, CM, κ.ά.
Έκδοση: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
ανά: Pavord, I, κ.ά.
Έκδοση: (2012)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
ανά: Prazma CM, κ.ά.
Έκδοση: (2021-06-01)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
ανά: Gao J, κ.ά.
Έκδοση: (2018-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
ανά: Menzella F, κ.ά.
Έκδοση: (2016-06-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
ανά: Pavord, I, κ.ά.
Έκδοση: (2017)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
ανά: Charlene M. Prazma, κ.ά.
Έκδοση: (2019-05-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
ανά: Chio Sakai, κ.ά.
Έκδοση: (2024-07-01)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
ανά: Berry, M, κ.ά.
Έκδοση: (2005)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
ανά: Wechsler, M, κ.ά.
Έκδοση: (2017)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
ανά: Buendía, JA, κ.ά.
Έκδοση: (2022)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
ανά: Jefferson Antonio Buendía, κ.ά.
Έκδοση: (2022-06-01)

Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts
ανά: Yuki Hoshino, κ.ά.
Έκδοση: (2022-04-01)